The new capability for the Radius VSM wearable monitor uses pattern-recognition technology to analyze continuous patient data and help clinicians identify early signs of opioid-related respiratory risk.
Masimo, a Danaher company specializing in pulse oximetry and other patient monitoring solutions, announced US Food and Drug Administration 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM wearable continuous patient monitor.
Enabled by Masimo’s next-generation smartSET pulse oximetry sensor platform, the new feature uses advanced pattern recognition that analyzes continuous physiologic data to help clinicians identify early signs of respiratory compromise in hospital patients receiving opioid therapy, according to a press release from the company.
This clearance represents the first implementation of Masimo’s opioid-induced respiratory depression detection capability in a hospital monitoring solution.
“Opioid-induced respiratory depression remains a critical patient-safety concern,” says Dr Basil Matta, chief medical officer at Masimo, in a release. “With OIRD detection, Masimo is bringing advanced pattern recognition to continuous, wearable monitoring to help clinicians identify earlier changes in a patient’s respiratory status that may not be apparent through traditional approaches. This capability reflects our ongoing focus on working closely with clinicians to address complex patient-safety challenges with meaningful innovation. OIRD detection on Radius VSM will help expand continuous monitoring from simple measurement to meaningful insight, supporting safer care throughout the hospital.”
Building on RD SET sensor technology, smartSET is engineered to unlock the value of continuous parameter insights by analyzing complex physiological patterns and relationships rather than relying on individual parameters alone, according to the press release. Its design also allows for future integration into additional hospital monitoring solutions.
Radius VSM is a wearable, tetherless, modular vital signs monitor designed to support continuous assessment of patient status throughout the hospital, with the ability to tailor monitoring to meet each patient’s needs. The opioid-induced respiratory depression feature includes visual alarms, which alert clinicians to changes in a patient’s condition and escalate as opioid-induced respiratory depression risk increases. The alarms are presented on the device’s display and can be relayed to remote and centralized monitoring stations.
Photo caption: Opioid-induced respiratory depression detection on Radius VSM
Photo credit: Masimo
